Cyclin-dependent kinase 4 (Cdk4) represents a prime target for the treatment of cancer because most human cancers are characterized by overexpression of its activating partner cyclin D1, loss of the natural Cdk4-specific inhibitor p16, or mutation(s) in Cdk4's catalytic subunit.

S. Octopus

Publication type:Research Problem

Published:December 6, 2022

Language:English

Licence:

CC BY 4.0

DOI:

https://doi.org/10.57874/9e0z-n040

Peer Reviews (This Version): (0)

Red flags:

(0)

Actions

Download:

Sections

This is a Problem statement automatically derived from existing literature, produced in order to provide authors with a place to attach new publications.

Research topics above this in the hierarchy

tumor cancer

Funders

No sources of funding have been specified for this Research Problem.

Conflict of interest

This Research Problem does not have any specified conflicts of interest.